Yeah. Love to talk about this. So one of the things that the mRNA vaccines enable us to do... so the reason that the mRNA vaccine was able to move so fast is.... mRNA is what's known as a platform therapeutic. We've mentioned this a little bit on this, this podcast so far. A platform therapeutic is really where you have a given molecule, so mRNA that is encapsulated in a lipid nanoparticle. And all of the molecular species are kind of known. And the only thing that you're changing with messenger RNA is the sequence of the... welll people are familiar with ATGC. But in the case of mRNA, it's actually AUGC, because thymine is switched to uracil. And so with the AUGC sequence of the messenger RNA, you can change that to be any sequence and that sequence can match any viral protein. That sequence will code for a viral protein through classic genetics and you can then switch in the sequence of any viral threat that exists out there. And so what I've been advocating for is that, again, we take this defensive look — this idea of vaccines for the national defense — knowing that one of the greatest threats that we face as a nation and as a species is that of the biological. Throughout history, biology and the microscopic and the basically invisible to us, has been shaping our lives. It changed how the Americas were founded.... when the settlers came and interacted with the natives that lived here in this country, how that proceeded had to do with disease, infectious disease that was that was brought along with those with those settlers. So we've always been shaped by this piece of biology. And it's always been a threat, though for the past 100 years, we've enjoyed an unbelievable period of peace time. Since Spanish influenza to the current pandemic, we've had our trials and tribulations, we've had polio, we've had HIV, we've had a number of different diseases come out, but we haven't had anything on the level of COVID. And so we have to think about how do we prevent this from happening? And the way we prevent this from happening is by taking these platform therapeutics, now that we know that this formulation works as a vaccine; this particle with a messenger RNA inside of it can be injected into the body and form immunity. And it's very easy to now recode, that mRNA rather than what it would take to say build a traditional vaccine, for every virus, which would create, you'd have to make a new process, it'd take multiple years for every single sort of virus and understanding it and building it, everything would have to be very niche. With platform technologies, we can just start encoding every viral antigen sequence that we can possibly think of. And so what I believe we should do is take the proactive step, where we create prototype vaccines against every known infectious virus, starting with the most high risk viruses. And then we create, even further vaccines, against other sorts of known antigens that could emerge, we create a monitoring system where we're constantly sequencing the viromes, the viral genomes that are found in wild animal species that are close to humans, such as bats and pangolins, which is where coronaviruses mostly come from. Sequencing these viruses, identifying new viruses and making new vaccines in a proactive way, and taking each one of these vaccines through what we call early safety trials. So the first six months of 2020, the first nine months of 2020 even, were spent proving out that the vaccine was safe, and you can do safety trials without an ongoing pandemic. You need a number of volunteers. You need money to spend on that, but it's a small amount of money. It's single digit millions of dollars to go from the mRNA technology we have today to a fully executed phase one safety trial. And we could do that for every single vaccine that we could possibly develop. And so what this allows us to do is, at the time of a new emerging pandemic, we can take this arsenal of already de-risked vaccines and begin right at the phase three level, which the phase three is that efficacy trial that was in the news in November and December, that has to do with 95% of efficacy, that was all over every headline... we can begin those trials, not in the fall, as we did in 2020; but on the same timeline, we can begin those in January, we can start deploying vaccines and be ready to roll out vaccines. By the time we get to the spring or the early summer, if we're looking at a 2020 roadmap, we can be ready to roll these out and really take this proactive defense, of course right now, our health, our public health defenses are so reactionary. To put it in context of the Defense Department, imagine if we waited until there was an attack on US soil until we made any tanks or any aircraft... we just waited and then the moment someone attacked us, we tried to spin up the manufacturer of fighter jets and aircraft carriers and build them all and deploy them then. Imagine how bad things would get in that interim time where we were we were waiting. So with defense, we take a very proactive role, and since infectious diseases is clearly one of the largest threats looming, we live in a time of unprecedented global peace for the most part, so how do we now talk about the these new threats, such as biological...? Both natural biological threats and biological warfare, which could also emerge in the future, we need to be prepared.